Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, PR China; Cardiovascular Research Institute, Wuhan University, Wuhan, 430060, PR China; Hubei Key Laboratory of Cardiology, Wuhan, PR China.
Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, PR China.
Biomed Pharmacother. 2020 Dec;132:110896. doi: 10.1016/j.biopha.2020.110896. Epub 2020 Nov 2.
Previous study has shown that Kv4.3, a main coding subunit generating cardiac transient-outward K current (Ito), can inhibit Ca/calmodulin-dependent protein kinase II (CaMKII) activity. Based on these observations, we speculate that over-expression of Kv4.3 gene could reverse not only Ito reduction but also cardiac remodeling in the rat myocardial infarction (MI) model.
Healthy male Sprague-Dawley (SD) rats were used to establish MI model by ligation of left anterior descending coronary artery, and adenovirus integrated with Kv4.3 gene (AD-Kv4.3) was delivered in infarct border zone by intramyocardial injection. The hearts were harvested for histological analysis (HE or Masson trichrome staining), western blot or patch clamp 4 weeks after MI. Our data showed that the application of AD-Kv4.3 could reduce myocardial infarct size and fibrosis, and its cardioprotective effects were similar with medicine therapy (combination of metoprolol and captopril). Moreover, Kv4.3 over-expression significantly improved MI-induced cardiac dysfunction and enhanced Ito density while decreasing corrected QT (QTc) intervals and cardiac electrophysiological instability. Western blot showed that Kv4.3 transfection reduced CaMKII, PLB-17 and ryanodine receptor2 (RyR2 Ser2814) phosphorylation level, at same time increased SERCA2 expression dramatically.
Over-expression of Kv4.3 can not only attenuate cardiac electrophysiological instability and cardiac performance, but also reduce myocardial infarct area and cardiac fibrosis. Like traditional anti-remodeling therapy-angiotensin converting enzyme inhibitor (ACEI) combined with β-adrenergic receptor blocker, over-expression of Kv4.3 seems to be an effective and safe therapy for both structural and electrical remodeling induced by MI via CaMKII inhibition.
先前的研究表明,Kv4.3 是产生心脏瞬间外向钾电流(Ito)的主要编码亚基,可抑制钙/钙调蛋白依赖性蛋白激酶 II(CaMKII)活性。基于这些观察结果,我们推测 Kv4.3 基因的过表达不仅可以逆转 Ito 的减少,还可以逆转大鼠心肌梗死(MI)模型中的心脏重构。
使用健康雄性 Sprague-Dawley(SD)大鼠通过结扎左前降支冠状动脉建立 MI 模型,并通过心肌内注射将整合 Kv4.3 基因的腺病毒(AD-Kv4.3)递送至梗死交界区。MI 后 4 周,对心脏进行组织学分析(HE 或 Masson 三色染色)、western blot 或膜片钳检测。我们的数据表明,AD-Kv4.3 的应用可以减少心肌梗死面积和纤维化,其心脏保护作用与药物治疗(美托洛尔和卡托普利联合治疗)相似。此外,Kv4.3 的过表达显著改善了 MI 诱导的心脏功能障碍,增加了 Ito 密度,同时缩短了校正 QT(QTc)间期和心脏电生理不稳定性。Western blot 显示,Kv4.3 转染降低了 CaMKII、PLB-17 和肌浆网钙释放通道 2(RyR2 Ser2814)的磷酸化水平,同时显著增加了 SERCA2 的表达。
Kv4.3 的过表达不仅可以减轻心脏电生理不稳定性和心脏功能,还可以减少心肌梗死面积和心脏纤维化。与传统的抗重构治疗——血管紧张素转换酶抑制剂(ACEI)联合β肾上腺素能受体阻滞剂一样,Kv4.3 的过表达似乎通过抑制 CaMKII 对 MI 诱导的结构和电重构具有有效且安全的治疗作用。